BioRestorative Therapies (FRA:9OF) Stock Based Compensation: €1.38 Mil (TTM As of Mar. 2026)


FRA:9OF BioRestorative Therapies Inc FRA:9OF
55 GF Score
Price €0.32
GF Value €1.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Stock Based Compensation?

BioRestorative Therapies FRA:9OF -5.95% 55 Stock Based Compensation is €1.38 Mil as of Mar. 2026. GuruFocus rates FRA:9OF with a GF Score™ of 55/100 and a GF Value™ of €1.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

BioRestorative Therapies's Stock Based Compensation for the three months ended in Mar. 2026 was €0.25 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €1.38 Mil.

BioRestorative Therapies Stock Based Compensation Related Terms

BioRestorative Therapies Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for BioRestorative Therapies's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies Stock Based Compensation Chart

BioRestorative Therapies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.45 11.91 7.14 2.69 2.84

BioRestorative Therapies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 0.41 0.34 0.38 0.25
FRA:9OF
55GF Score
BioRestorative Therapies Inc FRA:9OF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.38 Mil.

What does a Stock Based Compensation of €1.38 Mil mean?
BioRestorative Therapies (FRA:9OF) has a Stock Based Compensation of €1.38 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BioRestorative Therapies and its competitors.
Is BioRestorative Therapies' Stock Based Compensation too high?
BioRestorative Therapies' current Stock Based Compensation is €1.38 Mil. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Stock Based Compensation compare to CVKD and JSPR?
BioRestorative Therapies' Stock Based Compensation of €1.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BioRestorative Therapies and its competitors. BioRestorative Therapies's current Stock Based Compensation is €1.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.39, compared to a current price of €0.32 — trading 77.3% below its estimated fair value. The current Stock Based Compensation is €1.38 Mil. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Stock Based Compensation is €1.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.32 is trading 77.3% below its estimated GF Value™ of €1.39. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for FRA:9OF:

  • Stock Based Compensation: €1.38 Mil
  • GF Value™: €1.39 vs. price of €0.32 (77.3% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioRestorative Therapies Business Description

Other Exchanges BRTX:USA
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score

Get the complete analysis for FRA:9OF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price
€1.39
GF Value